Overview

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

Status:
Completed
Trial end date:
2020-04-14
Target enrollment:
Participant gender:
Summary
This open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and PK/PD of BDB-001 injection in patients with mild, or general COVID-19.
Phase:
Phase 1
Details
Lead Sponsor:
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Collaborator:
Beijing Defengrui Biotechnology Co. Ltd